SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Primary site must be bone (C400-C419). The most common bones involved are the vertebrae. The thoracic vertebrae are more commonly involved then the cervical or lumbar. Other common bones include the ribs, skull, pelvis, femur, clavical, and scapula.
Plasmacytoma is a localized collection of monoclonal plasma cells. Diagnosed on basis of: single bone lesion with histology consistent with a plasma cell tumor; absence of a plasma cell infiltrate in random bone marrow biopsies; no evidence of other bone lesions by radiographic examination; absence of renal failure; no hypercalcemia; no anemia.
This is a localized tumor in the bone consisting of monoclonal plasma cells. Complete skeletal radiographs (preferably MRI) show no other lesions.
There is no evidence of bone marrowplasmacytosis other than the solitary lesion. Vertebral lesions may be associated with symptomatic cord compression.
Patient presents with bone pain at the site of the lesion or with a pathological fracture. Soft tissue extension may produce a palpable mass. An M-protein is found in the serum or urine in 24-72% of patients.
Local control is achieved by radiotherapy. Plasma cells are usually easily recognizable in tissue specimens. Even when the diagnosis is apparent, determination of light chain type is suggested.
Plasma cell neoplasm was previously included as an alternate name for plasmacytoma. The phrase "plasma cell neoplasm" is an umbrella term used for many diseases, some of which are not reportable. If the only diagnosis is "plasma cell neoplasm," then do not report this case. If it is "plasma cell neoplasm" consistent with a plasmacytoma or multiple myeloma, then the case would be reportable.